IOVA Iovance Biotherapeutics Inc
Company Analysis
Latest News
🟢 Iovance Biotherapeutics is trading 4.24% up today
Iovance Biotherapeutics is trading 4.24% up at $8.96, continuing recent strength after gaining 5.65% on September 11, 2026. - Management highlighted stronger...
🟢 Iovance Biotherapeutics is trading 4.12% up today after stronger Amtagvi commercial momentum
Iovance Biotherapeutics is trading 4.12% up at $8.47 after management highlighted stronger Amtagvi commercial momentum. - Management discussed the momentum at...
Iovance Biotherapeutics Highlights Amtagvi Growth, Extending Cash Runway to 2028
Iovance Biotherapeutics reported strong commercial momentum for its melanoma therapy, Amtagvi, at the Wells Fargo 21st Annual Healthcare...
🔴 Iovance Biotherapeutics is trading 4.15% down today amid rate concerns after hotter-than-expected producer inflation
Iovance Biotherapeutics is trading at $8.08, down -4.15% on September 10, 2026, amid declining major U.S. indexes and heightened rate concerns after...
🔴 Iovance Biotherapeutics is trading 4.2% down today as oil prices top $100
Iovance Biotherapeutics is trading 4.2% down now at $8.34 amid broad market weakness, elevated oil prices above $100 and geopolitical tensions. - The Nasdaq...
🟢 Iovance Biotherapeutics is trading 4.03% up today amid biotech sector strength
Iovance Biotherapeutics is trading at $8.61, up 4.03% on September 2, 2026, alongside a 2.75% gain in the XBI biotech ETF amid positive patent news and...
🔴 Iovance Biotherapeutics is trading 4.24% down today
Iovance Biotherapeutics is trading 4.24% down now at $7.67 after no clear company-specific catalyst emerged in the August 31, 2026 search. • August 21...
🔴 Iovance Biotherapeutics is trading 4.32% down today, possibly on profit-taking
Iovance Biotherapeutics is trading 4.32% down at $8.07, with no clear company-specific negative catalyst emerging for August 26, 2026. - Zacks highlighted...
Iovance Biotherapeutics Highlighted as a Top Biotech Stock Pick
On August 26, 2026, Zacks Investment Research featured Iovance Biotherapeutics as one of five biotech stocks recommended for portfolios. The report highlighted...
🟢 Iovance Biotherapeutics is trading 4.44% up today amid 2.06% biotech-sector gains
Iovance Biotherapeutics is trading 4.44% up at $8.42, with biotech-sector momentum the strongest apparent driver as the sector advances 2.06%. - No fresh...
🔴 Iovance Biotherapeutics is trading 4.06% down today after sharp two-session rally
Iovance Biotherapeutics is trading 4.06% down at $8.62 after its sharp two-session rally; no new company-specific announcement explaining the August 21, 2026...
🟢 Iovance Biotherapeutics is trading 11% up today amid broader melanoma-biotech enthusiasm
Iovance Biotherapeutics is trading 10.58% up at $8.84, apparently driven by melanoma-biotech enthusiasm after positive Phase 3 vaccine results from Moderna and...
🟢 Iovance Biotherapeutics is trading 5% up today after positive Phase 3 melanoma-vaccine results
Iovance Biotherapeutics is trading 5% up at $8.39, apparently benefiting from continued biotechnology enthusiasm after Moderna and Merck reported positive...
🟢 Iovance Biotherapeutics is trading 10% up today on positive melanoma-vaccine results from Moderna and Merck
Iovance Biotherapeutics is trading 10% up at $7.74, as biotechnology stocks rally broadly after Moderna and Merck reported positive Phase 3 melanoma-vaccine...
🟢 Iovance Biotherapeutics is trading 9.5% up today as biotech stocks rally on Moderna results
Iovance Biotherapeutics is trading 9.5% up at $7.70, reversing the unexplained 4.6% pre-market decline reported before the August 19, 2026 open, amid a...
🔴 Iovance Biotherapeutics is trading 4.6% down in pre-market amid unexplained trading pressure
Iovance Biotherapeutics is trading 4.6% down at $6.71 in pre-market amid unexplained trading pressure, with no clear company-specific catalyst identified. -...
🟢 Iovance Biotherapeutics is trading 4.52% up today with no clear new catalyst
Iovance Biotherapeutics is trading at $6.82, up +4.52%, with no clear company-specific catalyst identified for August 14, 2026. • No clear company-specific...
🔴 Iovance Biotherapeutics is trading 4.01% down today despite broader U.S. indexes moving higher
Iovance Biotherapeutics is trading 4.01% down at $6.47, despite broader U.S. indexes moving higher on August 13, 2026; no clear company-specific announcement...
Iovance Announces Preliminary Q2 2026 Revenue of ~$99 Million, Beating Guidance
Iovance Biotherapeutics disclosed preliminary second-quarter 2026 financial results and a business update in a new corporate presentation. The company...
Iovance Biotherapeutics' second quarter revenue reached $99M as Amtagvi sales drive 66% growth
Iovance Biotherapeutics reported record financial results for the second quarter 2026, characterized by the accelerating commercial adoption of Amtagvi. The...